Drug Profile
AB 100501
Alternative Names: AB-1005-01; AB-1005-01/MRTULatest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator AlphaBeta Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Schizophrenia in United Kingdom
- 22 Jan 2016 Preclinical trials in Schizophrenia in United Kingdom (unspecified route)